Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Enterprise Value of -$987.7 million for Q1 2026, down 20.75% year-over-year from -$1.2 billion in Q1 2025, and down 13.8% quarter-over-quarter from -$867.9 million in Q4 2025.
Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Enterprise Value for 10 consecutive years, with -$987.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 20.75% year-over-year to -$987.7 million; the TTM figure through Mar 2026 stood at -$987.7 million (down 20.75% YoY), while the FY2025 annual figure was -$867.9 million, down 4.27% from the prior year.
- Enterprise Value eased to -$987.7 million in Q1 2026 per DNLI's latest filing, from -$867.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$817.9 million in Q1 2025 and bottomed at -$1.3 billion in Q4 2022.
- Historically, Enterprise Value has averaged -$1.0 billion across 5 years, with a median of -$957.5 million in 2022.
- On a YoY basis, Enterprise Value climbed as much as 32.24% in 2022 and fell as far as 54.4% in 2022.
- Denali Therapeutics' Enterprise Value stood at -$1.3 billion in 2022, then gained by 22.58% to -$1.0 billion in 2023, then rose by 19.54% to -$832.3 million in 2024, then dropped by 4.27% to -$867.9 million in 2025, then declined by 13.8% to -$987.7 million in 2026.
- Business Quant data shows DNLI's Enterprise Value at -$987.7 million in Q1 2026, -$867.9 million in Q4 2025, and -$848.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -710.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -710.47 Mn |
| Mar 31, 2026 | -987.68 Mn |
| Dec 31, 2025 | -867.88 Mn |
| Sep 30, 2025 | -848.20 Mn |
| Jun 30, 2025 | -898.95 Mn |
| Mar 31, 2025 | -817.93 Mn |
| Dec 31, 2024 | -832.33 Mn |
| Sep 30, 2024 | -836.56 Mn |
| Jun 30, 2024 | -896.04 Mn |
| Mar 31, 2024 | -936.87 Mn |
| Dec 31, 2023 | -1.03 Bn |
| Sep 30, 2023 | -1.11 Bn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -1.29 Bn |
| Dec 31, 2022 | -1.34 Bn |
| Sep 30, 2022 | -1.11 Bn |
| Jun 30, 2022 | -1.07 Bn |
| Mar 31, 2022 | -957.52 Mn |
| Dec 31, 2021 | -865.41 Mn |
| Sep 30, 2021 | -1.04 Bn |